Two Sigma Advisers’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,300
| Closed | -$459K | – | 505 |
|
|
2025
Q4 | $459K | Buy |
+2,300
| New | +$417K | ﹤0.01% | 1822 |
|
|
2025
Q2 | – | Sell |
-33,600
| Closed | -$5.06M | – | 2356 |
|
|
2025
Q1 | $5.06M | Buy |
33,600
+5,500
| +20% | +$922K | 0.01% | 788 |
|
|
2024
Q4 | $5.19M | Buy |
28,100
+11,800
| +72% | +$2.27M | 0.01% | 713 |
|
|
2024
Q3 | $3.21M | Sell |
16,300
-5,100
| -24% | -$1.06M | 0.01% | 865 |
|
|
2024
Q2 | $4.42M | Sell |
21,400
-2,800
| -12% | -$634K | 0.01% | 814 |
|
|
2024
Q1 | $6.56M | Sell |
24,200
-1,500
| -6% | -$358K | 0.02% | 668 |
|
|
2023
Q4 | $6.08M | Sell |
25,700
-100
| -0.4% | -$19.7K | 0.01% | 722 |
|
|
2023
Q3 | $5.06M | Sell |
25,800
-2,800
| -10% | -$575K | 0.01% | 729 |
|
|
2023
Q2 | $6.01M | Sell |
28,600
-11,200
| -28% | -$2.23M | 0.02% | 686 |
|
|
2023
Q1 | $8.03M | Sell |
39,800
-55,400
| -58% | -$12.6M | 0.02% | 621 |
|
|
2022
Q4 | $20.7M | Sell |
95,200
-151,100
| -61% | -$33M | 0.06% | 330 |
|
|
2022
Q3 | $48.5M | Buy |
246,300
+2,700
| +1% | +$583K | 0.14% | 164 |
|
|
2022
Q2 | $52.1M | Buy |
243,600
+64,300
| +36% | +$15.7M | 0.15% | 152 |
|
|
2022
Q1 | $50.9M | Buy |
179,300
+149,800
| +508% | +$46.2M | 0.14% | 162 |
|
|
2021
Q4 | $11.1M | Buy |
29,500
+6,600
| +29% | +$2.56M | 0.03% | 477 |
|
|
2021
Q3 | $9.45M | Buy |
+22,900
| New | +$9.51M | 0.02% | 537 |
|
|
2021
Q1 | – | Sell |
-8,400
| Closed | -$2.1M | – | 2591 |
|
|
2020
Q4 | $2.1M | Sell |
8,400
-43,100
| -84% | -$10.3M | 0.01% | 1235 |
|
|
2020
Q3 | $11.7M | Sell |
51,500
-23,700
| -32% | -$4.92M | 0.03% | 493 |
|
|
2020
Q2 | $13.1M | Buy |
75,200
+31,300
| +71% | +$5M | 0.04% | 459 |
|
|
2020
Q1 | $5.54M | Buy |
43,900
+42,000
| +2,211% | +$6.3M | 0.02% | 675 |
|
|
2019
Q4 | $290K | Sell |
1,900
-7,400
| -80% | -$1.02M | ﹤0.01% | 2075 |
|
|
2019
Q3 | $1.23M | Sell |
9,300
-6,200
| -40% | -$831K | ﹤0.01% | 1340 |
|
|
2019
Q2 | $2.2M | Sell |
15,500
-16,700
| -52% | -$2.27M | 0.01% | 1172 |
|
|
2019
Q1 | $4.68M | Sell |
32,200
-6,500
| -17% | -$854K | 0.01% | 858 |
|
|
2018
Q4 | $4.38M | Sell |
38,700
-15,454
| -29% | -$1.93M | 0.01% | 847 |
|
|
2018
Q3 | $7.29M | Sell |
54,154
-23,400
| -30% | -$2.89M | 0.02% | 683 |
|
|
2018
Q2 | $8.71M | Sell |
77,554
-5,196
| -6% | -$562K | 0.02% | 632 |
|
|
2018
Q1 | $8.83M | Buy |
82,750
+4,800
| +6% | +$517K | 0.02% | 636 |
|
|
2017
Q4 | $8.53M | Sell |
77,950
-48,000
| -38% | -$5.22M | 0.02% | 662 |
|
|
2017
Q3 | $13.6M | Sell |
125,950
-134,000
| -52% | -$13.8M | 0.04% | 478 |
|
|
2017
Q2 | $26.3M | Buy |
259,950
+25,145
| +11% | +$2.31M | 0.09% | 278 |
|
|
2017
Q1 | $21.1M | Buy |
234,805
+50,425
| +27% | +$4.28M | 0.07% | 351 |
|
|
2016
Q4 | $14M | Buy |
184,380
+150,600
| +446% | +$11.4M | 0.05% | 376 |
|
|
2016
Q3 | $2.81M | Buy |
+33,780
| New | +$2.83M | 0.01% | 873 |
|
|
2016
Q2 | – | Sell |
-59,080
| Closed | -$4.49M | – | 2067 |
|
|
2016
Q1 | $4.49M | Buy |
59,080
+12,800
| +28% | +$947K | 0.03% | 536 |
|
|
2015
Q4 | $3.72M | Sell |
46,280
-9,800
| -17% | -$707K | 0.02% | 532 |
|
|
2015
Q3 | $3.56M | Buy |
56,080
+2,800
| +5% | +$201K | 0.02% | 561 |
|
|
2015
Q2 | $3.75M | Sell |
53,280
-87,400
| -62% | -$6.47M | 0.03% | 574 |
|
|
2015
Q1 | $11.2M | Buy |
140,680
+61,200
| +77% | +$4.51M | 0.08% | 289 |
|
|
2014
Q4 | $5.06M | Sell |
79,480
-122,500
| -61% | -$7.68M | 0.04% | 484 |
|
|
2014
Q3 | $12.1M | Sell |
201,980
-45,900
| -19% | -$2.63M | 0.09% | 264 |
|
|
2014
Q2 | $13.3M | Sell |
247,880
-60,000
| -19% | -$3.29M | 0.1% | 228 |
|
|
2014
Q1 | $18.6M | Buy |
307,880
+256,400
| +498% | +$14.9M | 0.17% | 134 |
|
|
2013
Q4 | $2.73M | Buy |
51,480
+1,900
| +4% | +$95.4K | 0.03% | 604 |
|
|
2013
Q3 | $2.29M | Buy |
49,580
+600
| +1% | +$27.5K | 0.03% | 577 |
|
|
2013
Q2 | $2.01M | Buy |
+48,980
| New | +$2.1M | 0.03% | 514 |
|
Other funds holding CRL
VCM
VPM
Two Sigma Advisers's CRL Position: Q1 2026 in Review
Two Sigma Advisers sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 2,300 shares — an estimated $459K sold.
Two Sigma Advisers first reported a position in CRL in Q2 2013 and held it in 46 quarters. The position peaked at $52.1M in Q2 2022. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Two Sigma Advisers reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 2,300 Charles River Laboratories shares in Q1 2026, an estimated $459K.
- Two Sigma Advisers first reported a position in Charles River Laboratories in Q2 2013 and held it in 46 quarters.
- Two Sigma Advisers's Charles River Laboratories position peaked at $52.1M in Q2 2022.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.